Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

Dow Jones02-13

0820 GMT - Sanofi's abrupt move to replace CEO Paul Hudson with Merck KGaA's head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. "We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take." Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

February 13, 2026 03:21 ET (08:21 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611422131?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 16:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611422131","market":"hk","top_or_hot":-1,"title":"Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0820 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s abrupt move to replace CEO Paul Hudson with <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>'s head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 03:21 ET (08:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-13 16:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0820 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s abrupt move to replace CEO Paul Hudson with <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>'s head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 03:21 ET (08:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2611422131","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611422131","pubTimestamp":1770970860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0820 GMT - Sanofi's abrupt move to replace CEO Paul Hudson with Merck KGaA's head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNYNF":"Sanofi","SNY":"赛诺菲安万特","BK4588":"碎股","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4585":"ETF&股票定投概念","BK4007":"制药"},"translate_title":"赛诺菲首席执行官变动增加了近期的不确定性——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"SNY":0.9},"content_text":"0820 GMT - Sanofi's abrupt move to replace CEO Paul Hudson with Merck KGaA's head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2026 03:21 ET (08:21 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611422131","isCrawlerRequest":true}